BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 22119508)

  • 1. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
    Persson M; Engström G; Björkbacka H; Hedblad B
    Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
    Eugen-Olsen J; Andersen O; Linneberg A; Ladelund S; Hansen TW; Langkilde A; Petersen J; Pielak T; Møller LN; Jeppesen J; Lyngbaek S; Fenger M; Olsen MH; Hildebrandt PR; Borch-Johnsen K; Jørgensen T; Haugaard SB
    J Intern Med; 2010 Sep; 268(3):296-308. PubMed ID: 20561148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men.
    Haugaard SB; Andersen O; Hansen TW; Eugen-Olsen J; Linneberg A; Madsbad S; Olsen MH; Jørgensen T; Borch-Johnsen K; Jeppesen J
    Diabet Med; 2012 Apr; 29(4):479-87. PubMed ID: 22050462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation.
    Borné Y; Persson M; Melander O; Smith JG; Engström G
    Eur J Heart Fail; 2014 Apr; 16(4):377-83. PubMed ID: 24464777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.
    Lyngbæk S; Marott JL; Sehestedt T; Hansen TW; Olsen MH; Andersen O; Linneberg A; Haugaard SB; Eugen-Olsen J; Hansen PR; Jeppesen J
    Int J Cardiol; 2013 Sep; 167(6):2904-11. PubMed ID: 22909410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events.
    Sehestedt T; Lyngbæk S; Eugen-Olsen J; Jeppesen J; Andersen O; Hansen TW; Linneberg A; Jørgensen T; Haugaard SB; Olsen MH
    Atherosclerosis; 2011 May; 216(1):237-43. PubMed ID: 21354571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Food patterns, inflammation markers and incidence of cardiovascular disease: the Malmö Diet and Cancer study.
    Hlebowicz J; Persson M; Gullberg B; Sonestedt E; Wallström P; Drake I; Nilsson J; Hedblad B; Wirfält E
    J Intern Med; 2011 Oct; 270(4):365-76. PubMed ID: 21443679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects.
    Persson M; Hedblad B; Nelson JJ; Berglund G
    Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1411-6. PubMed ID: 17431184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cadmium exposure is associated with soluble urokinase plasminogen activator receptor, a circulating marker of inflammation and future cardiovascular disease.
    Fagerberg B; Borné Y; Barregard L; Sallsten G; Forsgard N; Hedblad B; Persson M; Engström G
    Environ Res; 2017 Jan; 152():185-191. PubMed ID: 27792942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease.
    Persson M; Östling G; Smith G; Hamrefors V; Melander O; Hedblad B; Engström G
    Stroke; 2014 Jan; 45(1):18-23. PubMed ID: 24253546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolism.
    Engström G; Zöller B; Svensson PJ; Melander O; Persson M
    Thromb Haemost; 2016 Mar; 115(3):657-62. PubMed ID: 26466866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of suPAR and hs-CRP on cardiovascular disease.
    Diederichsen MZ; Diederichsen SZ; Mickley H; Steffensen FH; Lambrechtsen J; Sand NPR; Christensen KL; Olsen MH; Diederichsen A; Grønhøj MH
    Atherosclerosis; 2018 Apr; 271():245-251. PubMed ID: 29402404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the inflammatory profiles for incidence of diabetes mellitus and cardiovascular diseases: a prospective study exploring the 'common soil' hypothesis.
    Bao X; Borné Y; Johnson L; Muhammad IF; Persson M; Niu K; Engström G
    Cardiovasc Diabetol; 2018 Jun; 17(1):87. PubMed ID: 29895294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.
    Samman Tahhan A; Hayek SS; Sandesara P; Hajjari J; Hammadah M; O'Neal WT; Kelli HM; Alkhoder A; Ghasemzadeh N; Ko YA; Aida H; Gafeer MM; Abdelhadi N; Mohammed KH; Patel K; Arya S; Reiser J; Vaccarino V; Sperling L; Quyyumi A
    Atherosclerosis; 2017 Sep; 264():108-114. PubMed ID: 28728756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRP and suPAR are differently related to anthropometry and subclinical organ damage.
    Lyngbæk S; Sehestedt T; Marott JL; Hansen TW; Olsen MH; Andersen O; Linneberg A; Madsbad S; Haugaard SB; Eugen-Olsen J; Jeppesen J
    Int J Cardiol; 2013 Aug; 167(3):781-5. PubMed ID: 22459389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
    Enocsson H; Wetterö J; Skogh T; Sjöwall C
    Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
    Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
    Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
    Mekonnen G; Corban MT; Hung OY; Eshtehardi P; Eapen DJ; Al-Kassem H; Rasoul-Arzrumly E; Gogas BD; McDaniel MC; Pielak T; Thorball CW; Sperling L; Quyyumi AA; Samady H
    Atherosclerosis; 2015 Mar; 239(1):55-60. PubMed ID: 25574858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects.
    Sørensen MH; Gerke O; Eugen-Olsen J; Munkholm H; Lambrechtsen J; Sand NP; Mickley H; Rasmussen LM; Olsen MH; Diederichsen A
    Atherosclerosis; 2014 Nov; 237(1):60-6. PubMed ID: 25222341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention.
    Lyngbæk S; Marott JL; Møller DV; Christiansen M; Iversen KK; Clemmensen PM; Eugen-Olsen J; Jeppesen JL; Hansen PR
    Am J Cardiol; 2012 Dec; 110(12):1756-63. PubMed ID: 22981263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.